Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 Next >
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Participate in the B. Riley Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Third Quarter 2023 Financial Results
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces $120 Million Private Placement of Ordinary Shares
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.